Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development

• Bando, Hiroshi

抄録

Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) have been recently effective for diabetes. Among them, subcutaneous injection and oral form of semaglutide (Rybelsus) are in focus, in which the latter has been examined in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) studies. Rybelsus could been invented for absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, due to 30-year process of innovation by Novo Nordisk. It shows clinical effects for diabetes and obesity. For PIONEER 9 and 10 trials, efficacy and safety were shown for 3, 7 or 14 mg of Rybelsus equivalent to subcutaneous liraglutide and subcutaneous dulaglutide for 52 weeks.

収録刊行物

• International Journal of Endocrinology and Diabetes

  International Journal of Endocrinology and Diabetes 5 (1), 130-, 2022-01-28

  Pubtexto Publishers

キーワード

• semaglutide
• Rybelsus
• Peptide InnOvatioN for Early diabEtes tReatment (PIONEER)
• absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
• Novo Nordisk

詳細情報

• CRID: 1050291158071231616
• NII論文ID: 120007192118
• ISSN: 26943875
• Web Site: http://repo.lib.tokushima-u.ac.jp/116746
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles